Review Article
Year: 2023 | Month: August | Volume: 13 | Issue: 8 | Pages: 64-69
DOI: https://doi.org/10.52403/ijhsr.20230810
Role of Empagliflozin - A New Sodium Glucose Co-Transporter 2 Inhibitor as a Monotherapy for Type 2 Diabetes Mellitus
Dr. P. Sharmila Nirojini1, Kowsalya V2, Kalpitha Mrinali V B3, Lavanya S4, Dharshini. S5
1Professor and Head, Department of Pharmacy Practice, Swamy Vivekanandha College of Pharmacy, Namakkal, Tamil Nadu, India
2,3,4Pharm.D. Intern, Swamy Vivekanandha College of Pharmacy and Vivekanandha Medical Care Hospital, Namakkal, Tamil Nadu, India
5B.Pharm. IV year, Swamy Vivekanandha College of Pharmacy, Namakkal, Tamil Nadu, India
Corresponding Author: Dr. P. Sharmila Nirojini
ABSTRACT
In 2010, around 4 million people worldwide lost their lives to diabetes-related causes. Inhibitors of SGLT2 are effective at controlling type 2 diabetes mellitus. By weakening the kidney's tubular barrier, empagliflozin lowers the amount of glucose excreted in urine. Empagliflozin was not related to increase in episodes of hypoglycemia as compared to placebo, with the exception of those taking a baseline sulfonylurea or insulin. The most common side effects of empagliflozin combinations were mild to moderate such as UTI, genital infection, and dysuria. Similar to the placebo, there was an equivalent rate of volume depletion in most cases. It is not suggested to be used during pregnancy or while lactating. It lowers cardiovascular disease mortality and heart failure hospitalizations in persons with type 2 diabetes.
Key words: Chemistry, Pharmacology, SGLT2 Inhibitor, Treatment, Safety, Efficacy.